Moleculin Biotech Stock Today
| MBRX Stock | USD 1.88 0.14 8.05% |
Performance0 of 100
| Odds Of DistressLess than 47
|
Moleculin Biotech is trading at 1.88 as of the 18th of January 2025; that is 8.05 percent increase since the beginning of the trading day. The stock's open price was 1.74. Moleculin Biotech has 47 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. The performance scores are derived for the period starting the 19th of December 2024 and ending today, the 18th of January 2025. Click here to learn more.
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas. The company has 3.19 M outstanding shares of which 82.13 K shares are now shorted by private and institutional investors with about 1.23 trading days to cover. More on Moleculin Biotech
Moving together with Moleculin Stock
Moving against Moleculin Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Moleculin Stock Highlights
| Chairman, CoFounder | Walter Klemp |
| Thematic Idea | Pharmaceutical Products (View all Themes) |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
| Financial Strength | |
Moleculin Biotech (MBRX) is traded on NASDAQ Exchange in USA. It is located in 5300 Memorial Drive, Houston, TX, United States, 77007 and employs 18 people. Moleculin Biotech is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.55 M. Moleculin Biotech conducts business under Biotechnology sector and is part of Health Care industry. The entity has 3.19 M outstanding shares of which 82.13 K shares are now shorted by private and institutional investors with about 1.23 trading days to cover.
Moleculin Biotech currently holds about 58 M in cash with (24.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.03, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Moleculin Biotech Probability Of Bankruptcy
Ownership AllocationMoleculin Biotech secures 3.3 % of its outstanding shares held by insiders and 15.34 % owned by institutional investors.
Check Moleculin Ownership Details
Moleculin Biotech Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Moleculin Biotech market risk premium is the additional return an investor will receive from holding Moleculin Biotech long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.04) | |||
| Jensen Alpha | (0.42) | |||
| Total Risk Alpha | (0.54) | |||
| Treynor Ratio | (0.25) |
Moleculin Stock Against Markets
Moleculin Biotech Corporate Management
| Louis Ploth | Independent Advisor | Profile | |
| ScD MD | Senior Officer | Profile | |
| Jacqueline Northcut | Consultant | Profile | |
| Donald Picker | Chief Officer | Profile | |
| Waldemar Priebe | Founding CoFounder | Profile |
Additional Tools for Moleculin Stock Analysis
When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.